Amrion
This article was originally published in The Tan Sheet
Executive Summary
FDA is investigating alleged violations of agency regulations "and other activities" committed by the company in 1989, when Amrion was "newly formed and under different management," firm says. Amrion said it submitted an offer of settlement to the Department of Justice but that it was rejected by DoJ on the basis that there is "some level of corporate liability." DoJ has issued a grand jury subpoena to the firm "for records to investigate the matter further," Amrion said, adding that it is cooperating with DoJ and FDA...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning